AtheroGenics to amend ARISE trial

AGIX submitted amendments to FDA for the Phase III ARISE trial of AGI-1067 to treat

Read the full 150 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE